Avenacy debuts generic Cyklokapron
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, is introducing tranexamic acid injection, which is a generic of Cyklokapron.
Tranexamic acid injection is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.
[Read more: Generic sterile injectables market to reach $196.2B by 2029]
“In less than one year since starting Avenacy, we have launched ten essential injectable medications—a formidable achievement and testament to our commercial expertise in specialty pharmaceuticals,” said Jeff Yordon, co-founder and CEO of Avenacy. “Since our company’s inception in October 2023, we have aimed to quickly deliver safe, effective, quality specialty injectables to hospitals and providers across the U.S., and the launch of tranexamic acid injection marks another important step in fulfilling this mission. The rest of 2024 is poised to be a transformative year for the business, as we remain focused on launching several additional products.”
Avenacy's tranexamic acid injection is available in 1,000 mg/10 ml (100 mg per ml) 10-pack single-dose vials. In line with Avenacy’s mission to champion patient safety and streamline patient care, tranexamic acid injection will feature the company’s highly differentiated packaging and labeling to support accurate medication selection, the company said.
[Read more: Avenacy releases magnesium sulfate in water for injection]
Avenacy will begin shipping tranexamic acid injection to wholesale partners this week. The company is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP-standards.
Tranexamic acid injection had a market value of approximately $28 million for the 12 months ending in June 2023, per IQVIA.